Analyst Rating Update on Merck & Company (MRK)

Merck & Company (MRK) has an average broker rating of 2.33, which is interpreted as a Buy, as rated by 12 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 8 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Merck & Company (MRK) : 12 investment research analysts covering Merck & Company (MRK) have an average price target of $62.67 for the near short term. The highest target price given by the Brokerage Firm to the stock is $80 and the lowest target is $53 for the short term. Analysts expect the variance to be within $7.44 of the average price.

Company shares have received an average consensus rating of Hold for the current week Also, Brokerage firm BMO Capital downgrades its rating on Merck & Company (NYSE:MRK). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on July 18, 2016.


Merck & Company (NYSE:MRK): The stock opened at $58.17 on Wednesday but the bulls could not build on the opening and the stock topped out at $58.30 for the day. The stock traded down to $57.18 during the day, due to lack of any buying support eventually closed down at $57.65 with a loss of -1.17% for the day. The stock had closed at $58.33 on the previous day. The total traded volume was 9,630,793 shares.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.